Revelation Biosciences
REVB
4 hedge funds and large institutions have $3.57M invested in Revelation Biosciences in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
100% more funds holding
Funds holding: 2 → 4 (+2)
4% more capital invested
Capital invested by funds: $3.44M → $3.57M (+$130K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$148K |
| 2 |
Citigroup
New York
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$49K |
| 2 |
Two Sigma Investments
New York
|
-$37K |
| 3 |
E
Ergoteles
New York
|
-$25K |
| 4 |
Jane Street
New York
|
-$22K |
| 5 |
VF
Virtu Financial
New York
|
-$17K |
REVB Hedge Fund Activity: Q2 2022 in Review
4 institutional investors reported a position in Revelation Biosciences (REVB) for Q2 2022, worth a combined $3.57M — up 3.8% from $3.44M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new REVB positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $148K. The largest seller was Citadel Advisors, cutting an estimated $49K.
- 4 institutional investors held Revelation Biosciences (REVB) as of Q2 2022, up from 2 in Q1 2022.
- Funds reported $3.57M of Revelation Biosciences stock for Q2 2022, up 3.8% quarter-over-quarter.
- 2 funds opened new Revelation Biosciences positions in Q2 2022 and 0 closed out, a net change of +2 holders.
- The largest Revelation Biosciences buyer in Q2 2022 was Bridgeway Capital Management, an estimated $148K added.
- The largest Revelation Biosciences seller in Q2 2022 was Citadel Advisors, an estimated $49K sold.
Based on aggregated 13F filings for Q2 2022.